Completed PHASE4 INTERVENTIONAL 1-arm NCT00352703

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation

Sponsor: Swedish Orphan Biovitrum

Conditions Multiple Myeloma Non-Hodgkin's Lymphoma

Interventions Kepivance (Palifermin)

Updated 6 times since 2017 Last updated: Oct 31, 2014 Started: Apr 30, 2006 Primary completion: Apr 30, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00352703, this PHASE4 trial focuses on Multiple Myeloma and Non-Hodgkin's Lymphoma and remains completed. Sponsored by Swedish Orphan Biovitrum, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swedish Orphan Biovitrum

Data source: Swedish Orphan Biovitrum

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.